WeissLaw LLP: NxStage Medical, Inc. Acquisition May Not Be in the Best Interests of NXTM Shareholders

NEW YORK, Aug. 8, 2017 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of NxStage Medical, Inc. (NASDAQ: NXTM) ("NXTM" or the "Company") in connection with the proposed acquisition of the Company by Fresenius Medical Care ("Fresenius").  On August 7, 2017, the Company announced a definitive agreement for Fresenius to acquire all outstanding shares of NXTM in a transaction valued at approximately $2.0 billion.  Under the terms of the agreement, the Company's shareholders will receive $30.00 in cash for each NXTM share they own.

WeissLaw is investigating whether NXTM's Board acted to maximize shareholder value prior to entering into the agreement.  Notably, at least one analyst set a target price of $33.00 per share.  Additionally, NXTM shares traded at $30.80, or $0.80 above the offer price, as recently as May.  Further, the Company recently announced positive financial results.  In a separate press release issued on August 7, 2017, NXTM reported total revenue of $96.2 million, representing an annual increase of 4% or $4.0 million, when compared to the $92.2 million reported in the same period of the previous year. 

Given these facts, WeissLaw is investigating whether NXTM's Board acted in the best interests of its public shareholders to maximize shareholder value prior to entering into the agreement.  If you own NXTM shares and would like more information about your rights or our investigation, or if you have information to share with us, please contact Mark Smilow by telephone at [phone] or by email at [e-mail].  

WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties.  We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases.  If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at [e-mail] or fill out the form on our website, http://www.weisslawllp.com/nxstage-medical-inc/

 

View original content:http://www.prnewswire.com/news-releases/weisslaw-llp-nxstage-medical-inc-acquisition-may-not-be-in-the-best-interests-of-nxtm-shareholders-300501363.html

SOURCE WeissLaw LLP

Copyright 2017 PR Newswire